ATTENZIONE IBDOLOGI! LA RESEZIONE ILEOCECALE PER IL MORBO DI CROHN POTREBBE AVERE UN RUOLO COME PRIMA TERAPIA RISPETTO AGLI ANTI-TNF! LO STUDIO PREDICT SU POPOLAZIONE DA “GASTROENTEROLOGY” (FREE).

Early Ileocecal Resection for Crohn’s Disease Is Associated With Improved Long-term Outcomes Compared With Anti-Tumor Necrosis Factor Therapy: A Population-Based Cohort Study Manasi Agrawal et al. Background & Aims Early Crohn’s disease (CD) treatment involves anti-tumor necrosis factor (TNF) agents, whereas ileocecal resection (ICR) is reserved for complicated CD or treatment failure. We compared long-term…

PER GLI EPATOLOGI E GLI INTERNISTI! QUALE DOSE DELLA SEMAGLUTIDE ORALE PER IL DIABETE ? UN EDITORIALE DA “LANCET” DI COMMENTO SU DUE TRIAL (FREE).

The pursuit of optimal semaglutide dosing in type 2 diabetes continues Christina H Sherrill , Andrew Y Hwang Diabetes remains a pressing global health concern, affecting approximately 540 million people worldwide.1 As prevalence continues to rise, diabetes places substantial burdens on individuals and health-care systems, influencing overall quality of life and health-care expenditures. Moreover, type 2…